Illustration: Rebecca Zisser/Axios
Novartis will acquire kidney disease treatment company Regulus Therapeutics for up to $1.7 billion — representing a 108% premium to its closing price Tuesday.
Why it matters: It's a glimmer of hope for the biotech M&A market, which has seen a slow start to the year.
